Human genes contain a dense array of diverse cis-acting elements that make up a code required for the expression of correctly spliced mRNAs. Alternative splicing generates a highly dynamic human proteome through networks of coordinated splicing events.
Cis- and trans-acting mutations that disrupt the splicing code or the machinery required for splicing and its regulation have roles in various diseases, and recent studies have provided new insights into the mechanisms by which these effects occur.
An unexpectedly large fraction of exonic mutations exhibit a primary pathogenic effect on splicing. Furthermore, normal genetic variation significantly contributes to disease severity and susceptibility by affecting splicing efficiency.
Genetic diseases
Numerous inherited human genetic disorders are caused by defects in pre-mRNA splicing.
There is a link between genetic variation and pre-mRNA splicing by identifying SNPs that correlate with heritable changes in alternative splicing but do not cause disease. This suggests that allele-specific alternative splicing is a mechanism that accounts for individual variation in the human population.
Cancer
Computational and experimental evidence has revealed that cancerous cells express transcript variants that are abnormally spliced, suggesting that mRNAs are more frequently alternatively spliced in cancerous tissues than in normal ones.
Cancerous tissues exhibit lower levels of alternative splicing than do normal tissues. Moreover, we found that the distribution of types of alternative splicing differs between cancerous and normal tissues.
The lower levels of alternative splicing in cancerous tissues might be a result of disruption of splicing regulatory proteins.
References
Kim E, Goren A, Ast G.Insights into the connection between cancer and alternative splicing.Trends Genet. 2008 Jan;24(1):7-10. PMID: 18054115
Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007 Oct;8(10):749-61. PMID: 17726481
Nissim-Rafinia M, Kerem B. The splicing machinery is a genetic modifier of disease severity. Trends Genet. 2005 Sep;21(9):480-3. PMID: 16039004
Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev. 2003 Feb 15;17(4):419-37. PMID: 12600935
Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet. 2002 Mar;18(3):123-7. PMID: 11858835
Bogdanov VY. Blood coagulation and alternative pre-mRNA splicing: an overview. Curr Mol Med. 2006 Dec;6(8):859-69. PMID: 17168737
Kuyumcu-Martinez NM, Cooper TA. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol. 2006;44:133-59. PMID: 17076268
Novoyatleva T, Tang Y, Rafalska I, Stamm S. Pre-mRNA missplicing as a cause of human disease. Prog Mol Subcell Biol. 2006;44:27-46. PMID: 17076263
Buratti E, Baralle M, Baralle FE. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res. 2006 Jul 19;34(12):3494-510. PMID: 16855287
Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays. 2006 Apr;28(4):378-86. PMID: 16547952